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Abstract
Background: The NeoAzure study has demonstrated that the use of the bisphosphonate zoledronic acid (Zol) in
the neoadjuvant setting increases the rate of complete response in primary breast cancer and therefore indicates
direct antitumor activity. The purpose of this study was to compare the antitumor effect of Zol with standard
chemotherapy in primary breast cancer cells using ATP-tumor chemosensitivity assay (ATP-TCA).
Methods: Breast cancer specimens were obtained from patients with breast cancer who underwent primary breast
cancer surgery at the Department of Obstetrics and Gynecology, Tübingen, Germany, between 2006 through 2009.
Antitumor effects of Zol, TAC (Docetaxel, Adriamycin, Cyclophosphamide) and FEC (5-Fluorouracil, Epirubicin,
Cyclophosphamide) were tested in 116 fresh human primary breast cancer specimens using ATP-TCA. ATP-TCA
results were analyzed with different cut-off levels for the half maximal inhibitory concentration (IC50), for IC90 and
for the sensitivity index (IndexSUM). Each single agent or combination was tested at six doubling dilutions from
6.25, 12.5, 25, 50, 100, and 200% of test drug concentrations (TDC) derived from the plasma peak concentrations
determined by pharmacokinetic data. The assay was carried out in duplicate wells with positive and negative
controls.
Results: The median IndexSUM value was lower for Zol than for the combined regimen FEC (36.8%) and TAC
(12.9%), respectively, indicating increased antitumor activity of Zol in primary breast cancer cells. The difference
regarding Zol and FEC was significant (p< 0.05). The median IC50 value for Zol (8.03% TDC) was significantly lower
than the IC50 values for FEC (33.5% TDC) and TAC (19.3% TDC) treatment (p< 0.05). However, the median IC90
value for Zol (152.5% TDC) was significantly higher than the IC90 value obtained with TAC (49.5% TDC; p< 0.05),
but similar to the IC90 value for FEC (180.9% TDC). In addition a significant positive correlation was observed for the
IndexSum of Zol and the ER status (p< 0.01).
Conclusion: Zoledronic acid has a strong antitumor effect on primary breast cancer cells in vitro which is equal or
superior to commonly used chemotherapeutic regimens for treating breast cancer.
Background
Bisphosphonates are standard of care in the treatment of
metastatic bone disease in women with breast cancer
and are also used to prevent and treat therapy-induced
osteoporosis in the adjuvant setting [1-7]. These com-
pounds significantly reduce bone pain and hypercalcae-
mia, maintain and improve quality of life while being
generally well tolerated. Treatment with bisphospho-
nates should be initiated after the first diagnosis of bone
metastases and should be continued life long based on
the current recommendations treatment (also under dis-
ease progression) [8].
There is growing evidence that bisphosponates may
have a direct antitumoric effect beyond their beneficial
effect on bone metastasis. Various investigations have
demonstrated that Zol can inhibit cell proliferation
in vitro, can trigger apoptosis and inhibit neovasculariza-
tion [9-11]. Similar effects have also been described for
other bisphosphonates. Several studies have demon-
strated a beneficial effect of the bisphosphonates clodro-
nate and Zol in preventing disease progression in the
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adjuvant setting in early breast cancer patients and to
improve disease free survival and overall survival as well
[12-14].
The NeoAzure study has demonstrated that the use of
the bisphosphonate Zol in the neoadjuvant setting
increases the rate of complete response in primary
breast cancer and therefore indicates direct antitumor
activity [15].
The purpose of the present study was to compare the
antitumor effect of Zol with standard chemotherapy in
primary breast cancer cells using ATP-TCA.
Results
In Table 1 the clinicpathological data for the tumor sam-
ples are presented. Tumor stages T1 and T2-4 were nearly
equally distributed. Five percent of the tumors were of G1,
about 60% were of G2 and about 36% were of G3 grade.
Nearly 80% of the samples were positive for ER and PR
expression, about 30% were HER2/neu positive. Most of
the tumors were from node-negative patients.
As shown in Figure 1 the median IndexSUM value was
36.8% and 12.9% lower for Zol than for the combined regi-
men FEC and TAC, respectively, indicating increased anti-
tumor activity of Zol in primary breast cancer cells. The
difference regarding Zol and FEC was significant (p< 0.05).
No significant difference was found between Zol and TAC
and between FEC and TAC.
Table 2 depicts that the median IC50 value for Zol
(8.03% TDC) was significantly lower than the IC50
values for FEC (33.5% TDC) and TAC (19.3% TDC)
treatment (p< 0.05). However, the median IC90 value
for Zol (152.5% TDC) was significantly higher than the
IC90 value obtained with TAC (49.5% TDC; p< 0.05),
but similar to the IC90 value for FEC (180.9% TDC).
A significant positive correlation was found for the
IndexSum of Zol and the ER status (n = 112; slope = 6.33;
95%CI = 2.13 to 10.5; p = 0.0035; Y = 130.8 + 6.33X;
r2 = 0.07).
Discussion
The first bisphosphonate was synthesized in 1865 [16].
Bisphosphonates are a further development of the pyro-
phosphates which are well-known in the chemical indus-
try. However, in contrast to pyrophosphates they are not
inactivated in vivo. In 1968, it was shown that bispho-
sphonates effectively inhibit osteoclast-mediated bone
resorption and since then they have become an integral
part in the management of benign and cancer-induced
bone disease [17].
A wealth of preclinical studies demonstrates that
bisphosphonates exhibit direct antitumor effects. In vitro
studies have clearly shown that bisphosphonates, in par-
ticular Zol, induce tumour cell apoptosis and inhibit
tumour cell adhesion, invasion and proliferation and
angiogenesis [9,18,19].
Up to now the antiproliferative and proapoptotic effect
of Zol was mainly proven in human breast cancer cell
lines. For the first time we have investigated the ex vivo
effect of Zol in freshly resected human breast specimen
and compared it to the effect of commonly used che-
motherapeutic regimen, i.e. FEC and TAC. The results
revealed that Zol was at least equal or even superior in
its antitumoric effect when compared to both combined
regimens. The significance of the found correlation be-
tween the IndexSums obtained with FEC, TAC and Zol
with T-, N- and ER-status of the tumors remains cur-
rently unknown.
Since our experiments have been performed with fresh
breast tumor samples which provide only limited quan-
tity of cells after disaggregation we were not able to
apply alternative test systems such as MTT or XTT
assay to validate the outcome. However, we have tested
three breast cancer cell lines in response to the cytotoxic
effect of Zol using the ATP-TCA with similar results.
The effector mechanisms of Zol have been investigated
by several groups. Their data point towards reversing
effects of Zol on cell proliferation and upregulation of
pro-apoptotic combined with downregulation of anti-
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apoptotic proteins and survival factors [19]. The mevalo-
nate pathway which is a target of Zol may be important
for these observations [20].
These and our results indicate that Zol and probably
all bisphosphonates may exert a direct antitumoric effect
on breast cancer cells beyond their antimetastatic effect
on bone matrix. Thus the use of bisphosphonate treat-
ment as adjuvant therapy in women with breast cancer
may have clinical significance.
This hypothesis is supported by some animal and clin-
ical studies investigating the use of Zol beyond the ac-
tion on cancer-induced bone loss. In a mouse model Zol
demonstrated a significant inhibition of breast cancer
tumor growth [17]. Further in vivo studies revealed syn-
ergistic antiproliferative effects of Zol in combination
with doxorubicin [20], docetaxel [21,22] as well as pacli-
taxel [23].
Intermittent addition of Zol can significantly reduce
serum levels of vascular endothelial growth factor
(VEGF) as compared to basal levels [24].
In ABCSG-12 the addition of Zol to endocrine therapy
was associated with a significant 36% improvement in
disease free survival (DFS) compared with endocrine
treatment alone, the median follow-up was 48 months
[25]. Furthermore, antitumour benefits of zoledronic
acid were observed outside bone.
Data from several pilot studies show that Zol poten-
tially clears disseminated tumour cells (DTCs) from the
bone marrow of patients with early breast cancer [26-
28] or in the neoadjuvant setting with locally advanced
breast cancer [29]. The presence of DTCs in the bone
marrow is a recognized risk factor for the subsequent
development of bone metastases, but longer term data
are required to establish the clinical relevance of these
findings.
The first subgroup analysis (n = 205) of the AZURE-
study (Does Adjuvant Zoledronic Acid RedUce Recur-
rence in Breast Cancer) of patients with neoadjuvant
chemotherapy revealed a synergistic effect of the com-
bination of chemotherapy with Zol on primary tumor
size [15]. The parameter residual invasive tumor size
(RITS) was significantly reduced by 43% (CT alone
27.4 mm vs. CT + Zol 15.5 mm; p = 0,006) and patho-
logical complete response rate improved by 69% (CT
alone 6.9% vs. CT + Zol 11.7%; p = 0.146), which, how-
ever, was not statistically significant.
The mechanism(s) by which Zol may trigger a direct
antitumoric action is currently not known. It inhibits
farnesyl diphosphate synthase within the mevalonate
pathway and, through this mechanism, is a potent in-
hibitor of osteoclast-mediated bone resorption. The
mevalonate pathway is known to be probably involved in
cancer development.
Our data for the first time suggest a positive correl-
ation between the efficacy of Zol and the ER status. A
possible association between the efficacy of Zol and the
presence of ER on inhibition of tumor cell growth could
be shown in two in vitro experiments that revealed that
ER-negative cell lines are inhibited in their growth by
Zol worse than ER-positive cell lines [10,11]. However,
in other experimental studies the efficacy of Zol was
similar in ER-negative and ER-positive cell lines [20] or
even more pronounced in the ER-negative cell line [30].
Interestingly, in the Women’s Health Initiative trial on
bisphosphonate use and breast cancer incidence a signifi-
cant lower incidence of about 30% of ER-positive breast
cancers was found in bisphosphonate users than in











Figure 1 Median values of IndexSum (25 and 75% quantiles; min, max)) of zoledronic acid (Zol) in comparison to FEC and TAC
(* p< 0.05 vs. FEC).
Table 2 IC90 and IC50 values (median %TDC; 25 and 75
quantiles) of zoledronic acid (Zol) in comparison to FEC
and TAC
Compound IC 90 IC 50
Zol 152.5 (36.3/217.8)+ 8.0 (4.6/18.3)*
FEC 180.9 (101.7/229.7) 33.5 (11.9/75.9)
TAC 49.5 (39.4/86.8) 19.3 (7.3/29.2)
+ p< 0.05 vs. TAC; * p< 0.05 vs. FEC and TAC.
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dependence of Zol from ER status remains unknown so
far. Hints might be derived from prostate cancer, since
in the prostate a dysregulated cellular growth is
mediated by inhibiting the rate-limiting pathway step in
cholesterol synthesis, thereby decreasing isoprenylate
intermediates, decreasing cholesterol rich cellular mem-
brane domains, and down-regulating androgen and es-
trogen receptors [32]. We therefore speculate that
expression of ER might point towards high activity of
cholesterol synthesis pathway and therefore high effect
of blocking the mevalonate pathway by Zol. Further re-
search is necessary to reveal this topic in more detail.
The Zol concentrations used in the present study were
in the range of 0.625 to 20 μg/ml and the IC50 value
was 1 μg/ml. The physiological plasma concentrations
(Cmax) after infusion of Zol are in the range of 0.2 to
0.4 μg/ml within 24 h [33]. Thus the effective in vitro
Zol concentrations were comparable to in vivo plasma
concentrations.
Conclusions
In summary zoledronic acid appears to elicit a strong
antitumor effect on primary breast cancer cells in vitro
which is equal or superior to commonly used che-
motherapeutic regimens for treating breast cancer.
Methods
Tumor specimens
116 fresh human primary breast cancer specimens
obtained from patients who underwent surgery at the
Department of Obstetrics and Gynecology, Tübingen,
Germany, between 2006 through 2010, were included in
the study. The ATP-TCA was performed as a routine
procedure immediately after surgery using the remaining
part of the primary tumor specimen not needed for
histopathology. All patients provided their informed
consent and the study design was approved by the local
Ethics Committee.
In vitro ATP-TCA
Chemosensitivity was assessed using the ATP-TCA kit
(TCA-100; DCS Innovative Diagnostik Systeme, Ham-
burg, Germany). The ATP-TCA has been previously
described in detail elsewhere [34]. Briefly, surgical biop-
sies (1-2 cm3) were taken during primary surgery.
Tumor cells were isolated by mechanical dissociation
and enzymatic treatment with Collagenase Worthington
Typ CLS III (Biochrom, Berlin, Germany) to obtain a
single cell suspension. Dissociated epithelial cells were
counted and assessed for viability using trypan-blue ex-
clusion. A minimum of 7,500 viable cells was deter-
mined as the cut-off requirement and were then seeded
into each well of a 96-well polypropylene microplate.
Cells were incubated for 5 days at 37 °C/5% CO2 in
complete assay medium (DCS Innovative Diagnostik
Systeme) and treated with different test drug concentra-
tions (TDC) in duplicates at six different doses. Two
controls were included in each plate: a no drug control
consisting of media only (M0) and a maximum inhibitor
(MI) control which kills all cells present. At the end of
the 5 day-incubation period, remaining cells were lysed
by the addition of tumor cell extraction reagent (DCS
Innovative Diagnostik Systeme). An aliquot of the lysate
from each well was added to corresponding wells in a
white 96-well microplate (Thermo Life Sciences, Basing-
stoke, UK) followed by addition of luciferin-luciferase re-
agent. The light output corresponding to the level of
ATP present was measured using a luminometer (Bert-
hold, Hamburg, Germany) and analyzed with custom
software to provide both numerical and graphical
results. Luminescence measurements are directly related
to ATP levels and enable to determine the percentage of
growth inhibition by reference to the control wells
included with each plate.
Drugs
Zol, TAC (docetaxel, adriamycin, cyclophosphamide)
and FEC (5-fluorouracil, epirubicin, cyclophosphamide)
were used in this study. Each single agent or combin-
ation was tested at six doubling dilutions from 6.25,
12.5, 25, 50, 100, and 200% of TDC derived from the
plasma peak concentrations determined by pharmacoki-
netic and clinical information (10). Standard 100% TDC
values were 1.29 μM for Zol, 17.3 μM for 5-fluorouracil,
0.088 μM for epirubicin, 1.24 μM for docetaxel and
1.11 μM for cyclophosphamide.
Data analysis
ATP-TCA results were interpreted and compared by
using the following calculation methods: (a) IC90 and
IC50: comparing the drug concentrations that achieve
90% or 50% growth inhibition in vitro, which is calculated
by interpolation (7) and (b) a sensitivity index (Index-
SUM): calculated by summing the percentage of tumor
growth inhibition (TGI) at each concentration tested:
IndexSUM =600− sum of % TGI at 200, 100, 50, 25, 12.5,
and 6.25% TDC (11). The total inhibition of growth
results in an IndexSUM of 0 and no inhibition of growth
at any concentrations provides an IndexSUM of 600. The
Wilcoxon-Rank test was used to compare the different
regimen. A p-value of <0.05 was considered to indicate
statistical significance. Ex vivo test results obtained with
the tumor specimen were tested for correlation with
tumor data according to the TNM and receptor status
using regression analysis. All statistics were calculated
with JMP 3.2.1 (SAS Institute, Cary, NC, USA).
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Immunohistochemical technique
Expression of estrogen and progesterone receptors (ER
and PR) and HER2/neu was determined as descibed
previously [35].
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